{"name":"Advanced Accelerator Applications","slug":"advanced-accelerator-applications","ticker":"","exchange":"","domain":"","description":"Advanced Accelerator Applications is a France-based pharmaceutical group, specialized in the field of nuclear medicine. \nThe group operates in all three segments of nuclear medicine to diagnose and treat serious conditions in the fields of oncology, neurology, cardiology, infectious and inflammatory diseases.","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"LUTATHERA","genericName":"LUTATHERA","slug":"lutathera","indication":"Other","status":"marketed"},{"name":"PSMA-11","genericName":"PSMA-11","slug":"psma-11","indication":"Other","status":"marketed"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"L-Lysine","genericName":"LYSINE","slug":"lysine","indication":"Itchy skin","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"177Lu-DOTA0-Tyr3-Octreotate","genericName":"177Lu-DOTA0-Tyr3-Octreotate","slug":"177lu-dota0-tyr3-octreotate","indication":"Neuroendocrine tumors (NET) with somatostatin receptor expression","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"arginine/lysine","genericName":"arginine/lysine","slug":"arginine-lysine","indication":"Immune support (specific indication unclear)","status":"marketed"}]}],"pipeline":[{"name":"L-Lysine","genericName":"LYSINE","slug":"lysine","phase":"marketed","mechanism":"Glutathione reductase, mitochondrial","indications":["Itchy skin","Painful skin","Red skin","Irritated skin","Anxiousness"],"catalyst":""},{"name":"177Lu-DOTA0-Tyr3-Octreotate","genericName":"177Lu-DOTA0-Tyr3-Octreotate","slug":"177lu-dota0-tyr3-octreotate","phase":"phase_3","mechanism":"177Lu-DOTA0-Tyr3-Octreotate is a radiolabeled somatostatin analog that binds to somatostatin receptors on neuroendocrine tumor cells and delivers targeted radiation therapy.","indications":["Neuroendocrine tumors (NET) with somatostatin receptor expression","Gastroenteropancreatic neuroendocrine tumors (GEP-NET)"],"catalyst":""},{"name":"LUTATHERA","genericName":"LUTATHERA","slug":"lutathera","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"PSMA-11","genericName":"PSMA-11","slug":"psma-11","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"arginine/lysine","genericName":"arginine/lysine","slug":"arginine-lysine","phase":"marketed","mechanism":"Arginine and lysine are amino acids that support immune function and may enhance natural killer cell activity and protein synthesis.","indications":["Immune support (specific indication unclear)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxPdFVOUFRyM0Fnb3EyYWtqZ1duZGhmMUxaaVA3LXEwYlBSOVBoSmhUWnYwV1ItbEZ6Qmh6QXY0U2tiSUhFY0VGOGRvOFVEZmlvSWNrNWpSck1KVVpCTUhsSWtfWVVaTjJhdWxtdGg5ajl3RC1SX3JkWFNUcnpNM05DMlQ2V2s4SWcxdF9VUw?oc=5","date":"2025-08-28","type":"pipeline","source":"Yahoo Finance","summary":"Next Generation Drug Conjugates Market Report 2025-2035, with Profiles of Advanced Accelerator Applications, Alnylam Pharmaceuticals, Arrowhead, Dicerna Pharmaceuticals, Geron, & Ionis Pharmaceuticals","headline":"Next Generation Drug Conjugates Market Report 2025-2035, with Profiles of Advanced Accelerator Applications, Alnylam Pha","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNOXFySURaR0lEeThFa3ZoeG1zQnlHVHZldXVCa29uemY1QllpOEgtVWV2c0plWHpkeUoxODJUN3hfSEtWTjI1ZFVXWVpfZDVtTWdBZzhEWi05S3hmZkNmTFJuSVFzYU9HUzNDMExFZE9uUjg3cGM2ZVFBNS1ydEI3TlN6eHlyTmNodU5Ucmx3?oc=5","date":"2025-06-13","type":"pipeline","source":"Insightace Analytic","summary":"Some of the Major Key Players in the Next Generation Drug Conjugates Market are - Insightace Analytic","headline":"Some of the Major Key Players in the Next Generation Drug Conjugates Market are","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQNUtrN3BhNU93alk0cGVCNXhBb1E1SDVkOE9xV1ItY18xQUQ4NTJXRUNwZDlOdkdLaTl1RnRXOVUwT1FRT3pBTjNLR2lyRkEzMDcyOFZjQkE0elA3TEx6UTNBYWpjbXlVWWpCMnVsSzZrdzNBbVRESjBKcnpwemprajVpeWlXNXNfQlBTWHB3?oc=5","date":"2024-12-10","type":"deal","source":"Siemens Healthineers","summary":"Siemens Healthineers Acquires Advanced Accelerator Applications Molecular Imaging - Siemens Healthineers","headline":"Siemens Healthineers Acquires Advanced Accelerator Applications Molecular Imaging","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOc1ZoQkhaRHdEUEw1TnR2NEswNHNHNXNWLXFmYXJwN1hYMmF2UF9ZVU0zQ2ZacUVKRWhkQUhKWURNMVR1eDNHeHNJc01tTVNXVzZNdE02eTZ5MlBDQkNUNGV5aVhraHJjTEEzUUdKbGxveXZSaldhZ18xb2JTNUpGV3FheHlORURFaHJRVHI5VWFFNHhjbnBiTw?oc=5","date":"2024-12-10","type":"deal","source":"MassDevice","summary":"Siemens Healthineers acquires Novartis molecular imaging business - MassDevice","headline":"Siemens Healthineers acquires Novartis molecular imaging business","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxPdVp0V0dGNWpJU3FCM2gwcnZFeTJJcTZsenM3TFNNSlR3S3N0RjNjZFNBdHdieWpReXRuRzFlUmozakVuSEFXblgteENkZ2E4VWNPby12elo2YzV4R0RqQ04wYnRaUVpXSjBxS0tDUWtGV0dxOExKMzJHNVBDSFBBMDRpTUV2VWdBTjBLYzRzZjQ?oc=5","date":"2024-08-26","type":"pipeline","source":"pharmaphorum","summary":"Healthineers offers €200m for Novartis radiodiagnostics unit - pharmaphorum","headline":"Healthineers offers €200m for Novartis radiodiagnostics unit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQTHlqaXdja0lZWVdFM0VHRTZlX2VucUdiU21GUDY4alVkSTlyOWZ6NU52dWl0aFNBNjF2MXdYMERvUkx5d3NncFQyU0U3MXhyYjVwdF9sU1ZlYUk1bnB1Nkw0VUI2bDVzaEFCT0UzcFVJTExaN2FKMkhfZXNTMGdZYkdLaXZMRVV4dWtJNng1OXRQX0dyZGN6M3htdk5YcEVlSGpF?oc=5","date":"2020-10-19","type":"pipeline","source":"WFYI","summary":"Pharmaceutical Company Breaks Ground On Indiana Manufacturing Site - WFYI","headline":"Pharmaceutical Company Breaks Ground On Indiana Manufacturing Site","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxQcGtvR3JWal9HT2VLaHlhcFhMRmlSZnlEVHlvOWYyc3lhWDlETkpoN2ZiUk5EUmNrVlFxa1FVOVZmSkdxT1RranR5NjM2N1pVbUxodGtpN09BRFh0OWhJVE9BcEt2Q0h1b3lrRjYwV01lSnZJMURYQ19OZU44YV9DMzVZTHlpSkNFNmk5QV82aTFva2ZnRUZBYlk4Nm0zaUFMOHRDVGI5SXY4Zjc4QjhOWEdvdE5NaVluRU1CQ1pVZjMzOGNOX2o4QlphSHZ0ZGhTd0xSTXJiRTlxazZrVVpreHNncHo2MjFiaTZQbGZkbEJRRmNyY1E?oc=5","date":"2018-01-22","type":"pipeline","source":"GlobeNewswire","summary":"Advanced Accelerator Applications Announces Completion of $3.9 Billion Novartis Tender Offer - GlobeNewswire","headline":"Advanced Accelerator Applications Announces Completion of $3.9 Billion Novartis Tender Offer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxOMUJIYzB6aDYzVGE0d3ByWFRuVUxONk0xZE0xdEplLUxQTU9lZlMxZVZfczlvYzV5ZnJnbGJpMTVmblBma09sRFp1RlA0MElVZ0dUUll4eWNWSnJMOE8zUDZZYmlNSVh1cEJIMmdQb1pDSlI3R3JSVXlpZGRoOU5jVDBOeDJ5Yk5iRXFHUzhaZkRyaTBrbXNtYW16cEp3bTBnT0xMUUJuak5lTWh0X0gwRjdaazRpTEU2RXcyY1NUeVd0Zk9SVE1HRWFMa29GWmw5N1JwSnQ4OXNmaThpNF9lSg?oc=5","date":"2017-10-30","type":"pipeline","source":"Novartis","summary":"Novartis announces the planned acquisition of Advanced Accelerator Applications to strengthen oncology portfolio - Novartis","headline":"Novartis announces the planned acquisition of Advanced Accelerator Applications to strengthen oncology portfolio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNX1Vha3pxa01LTGszZVlCaU9IczJkZTJ0WWgyaDR6VVRhMndjNWhKMDZuX3pUbktmZEp1elFrNncteGJXRGlDNkcxaVpjWnFUX3FYdWN1N1MxUERyNURSMXRLNVRHQ2JmNVk3eWVvNldQOEE1a1JaM2pmNG5HbEo0RmdqQ1MtWHd4S0hibGh4Q3Rma0J3QU5ISENJTHpxLXhyWlBDME1lZi1WOFZjWUVienBaeW1RQQ?oc=5","date":"2017-10-30","type":"deal","source":"Fierce Pharma","summary":"Novartis snags blockbuster hopeful Lutathera in $3.9B deal for Advanced Accelerator - Fierce Pharma","headline":"Novartis snags blockbuster hopeful Lutathera in $3.9B deal for Advanced Accelerator","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQdG9MWjlIZzJjUjdHQ2RkU3FVZzFfYVU0R0NRamZsTHFXeWZPdGF2R3VHa2toNm12bDhER2c2SElnNXRQSWtUS0VTeWJ5Q3lIb3JGcGVnamhfcXZ3aUplREpZaFoxMWdubGdFb1dhdXFWUGhvWHR1ZU02MkRxYXpibVNHV19wNVJDRXUzYlZMaFdUWDlreF9QTWVhVS11R1VJVndfcWU3cndObFZGZVItN3hoWWJEWTNlVlpN?oc=5","date":"2017-10-30","type":"deal","source":"BioPharma Dive","summary":"Novartis bolsters oncology with $3.9B Advanced Accelerator buy - BioPharma Dive","headline":"Novartis bolsters oncology with $3.9B Advanced Accelerator buy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNWFNJWUpubThCaWZNVnJnTTNZbVdIbXFvN2k3LVp2Slk0T0EzWjJGZzFVcjV3bVNMR1JlN0pvQWtHUXd0aS1JTDRaOXhLSS1IeGgxdG9BMmROMTJkZ3Jaald6eGlaMmQwbXl0bHBncHV4UnhSTzlPN2JydTFaSW5kVTQ5bnI4b1N4UWltaUMyYXk4WjRMR1Q2NzFPeWpRWEx4ZmZ0WkxFUEE?oc=5","date":"2017-10-30","type":"pipeline","source":"drugdiscoverytrends.com","summary":"Novartis Plans $3.9B Acquisition Of Advanced Accelerator Applications - drugdiscoverytrends.com","headline":"Novartis Plans $3.9B Acquisition Of Advanced Accelerator Applications","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPc3l1WEZ5OWJud0NxWVRacVdKdnVVeWlhWlE5dWt5MGk0Y0NpTGpvVWV5UzdTOWcxYXJZejh1SGJjWTI2V1dMWkdUa2t4Uy1ReUR5Y2dVUG9MQko3bHpGTFNBWExDQTAzOEc2OVRNMk8ySFZQZzk3NjZtRnk3SW5KbmFFV3B3Vml0UVMybDNEb0JIRlZRM2FwalJjQ2ZhME0?oc=5","date":"2017-10-30","type":"pipeline","source":"WSJ","summary":"Novartis to Pay $3.9 Billion for Radio-Pharmaceuticals Firm - WSJ","headline":"Novartis to Pay $3.9 Billion for Radio-Pharmaceuticals Firm","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"marketed":4,"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}